Symptomatische hypertrophe obstruktive Kardiomyopathie (NYHA Klasse II–III
G-BA action
final resolution
2024-02-01
Evidence-checked summary
The G-BA found a hint of considerable added benefit for Erwachsene mit symptomatischer hypertropher obstruktiver Kardiomyopathie (NYHA Klasse II–III). The appropriate comparator was - Therapie nach ärztlicher Maßgabe unter Berücksichtigung von nicht-vasodilatierenden Betablockern, Verapamil und Diltiazem. The G-BA issued a final resolution on 2024-02-01. The official page states that it took effect as follows: 01.02.2024. The page lists Arzneimittel-Richtlinie, Anlage XII: Nutzenbewertung nach § 35a SGB V as the normative target.
This is the latest validated public action attached to this case. It is separate from the IQWiG assessment result.
Final benefit result
Patient group
Erwachsene mit symptomatischer hypertropher obstruktiver Kardiomyopathie (NYHA Klasse II–III)
Hint of considerable added benefit
Comparator
- Therapie nach ärztlicher Maßgabe unter Berücksichtigung von nicht-vasodilatierenden Betablockern, Verapamil und Diltiazem
Official case record
No inferred stages
Consultation record
2023-12-11
51 parsed turns
Oral hearing: Mavacamten (Symptomatische hypertrophe obstruktive Kardiomyopathie (NYHA Klasse II–III))
Official Wortprotokoll · 11 pages
IQWiG comparison
IQWiG assessment findings and the later G-BA action are separate records. Open both to compare them.
A23-76
matched
Mavacamten (cardiomyopathy) – Benefit assessment according to §35a Social Code Book V
Official assessment PDF · 54 pages
G-BA decisions
2024-02-01
final resolution
The G-BA found a hint of considerable added benefit for Erwachsene mit symptomatischer hypertropher obstruktiver Kardiomyopathie (NYHA Klasse II–III). The appropriate comparator was - Therapie nach ärztlicher Maßgabe unter Berücksichtigung von nicht-vasodilatierenden Betablockern, Verapamil und Diltiazem. The G-BA issued a final resolution on 2024-02-01. The official page states that it took effect as follows: 01.02.2024. The page lists Arzneimittel-Richtlinie, Anlage XII: Nutzenbewertung nach § 35a SGB V as the normative target.
3 official documents · 4 cited claims
Official sources